KB001-A / Humanigen - LARVOL DELTA

Further Preclinical Development of an Clinically Effective Bio-therapeutic Against P orphyromonas gingivalis (AAIC 2021) - "KB-001 a murine IgG1 binds directly to a unique hetero-multimer antigen involved in the bacterial cargo IX transporter secretion protein complex through a high affinity bi-valent binding (kD 10 -8-9 ). About 40-60 antibody molecules bind to emerging OMVs per bacterial are observed. In addition isolated OMVs demonstrate binding to the outer and inner membranes."

Preclinical • Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Dyslipidemia • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Myocardial Infarction • Oncology • Type 2 Diabetes Mellitus

[VIRTUAL] Further Preclinical Development of an Clinically Effective Bio-therapeutic Against P orphyromonas gingivalis (AAIC 2021) - "KB-001 a murine IgG1 binds directly to a unique hetero-multimer antigen involved in the bacterial cargo IX transporter secretion protein complex through a high affinity bi-valent binding (kD 10 -8-9 ). About 40-60 antibody molecules bind to emerging OMVs per bacterial are observed. In addition isolated OMVs demonstrate binding to the outer and inner membranes."

Preclinical • Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Dyslipidemia • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Myocardial Infarction • Oncology • Type 2 Diabetes Mellitus

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. (PubMed, Cochrane Database Syst Rev) - "We could not identify an antibiotic adjuvant therapy that we could recommend for treating of lung infection in people with cystic fibrosis. The emergence of increasingly resistant bacteria makes the reliance on antibiotics alone challenging for cystic fibrosis teams. There is a need to explore alternative strategies, such as the use of adjuvant therapies. Further research is required to provide future therapeutic options."

Clinical • Journal • Review • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. (PubMed, J Cyst Fibros) - "KB001-A was safe and well-tolerated and associated with a modest FEV1 benefit and reduction in select sputum inflammatory markers (IL-8). KB001-A was not associated with an increased time to need for antibiotics. The lack of efficacy seen with KB001-A may be due, in part, to the low levels of the type III secretion proteins previously reported in sputum of CF patients chronically infected with Pa."

Clinical • Journal